Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 179

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Targeting macrophage Histone deacetylase 3 stabilizes atherosclerotic lesions

Open access
Hoeksema, Marten A, Gijbels, Marion JJ, Van den Bossche, Jan, van der Velden, Saskia, Sijm, Ayestha, Neele, Annette E, Seijkens, Tom, Stöger, J Lauran, Meiler, Svenja, Boshuizen, Marieke CS, Dallinga‐Thie, Geesje M, Levels, Johannes HM, Boon, Louis, Mullican, Shannon E, Spann, Nathanael J, Cleutjens, Jack P, Glass, Chris K, Lazar, Mitchell A, de Vries, Carlie JM, Biessen, Erik AL, Daemen, Mat JAP, Lutgens, Esther, de Winther, Menno PJ·2014·EMBO Molecular Medicine

Abstract

Macrophages are key immune cells found in atherosclerotic plaques and critically shape atherosclerotic disease development. Targeting the functional repertoire of macrophages may hold novel approaches for future atherosclerosis management. Here, we describe a previously unrecognized role of the epigenomic enzyme Histone deacetylase 3 (Hdac3) in regulating the atherosclerotic phenotype of macrophages. Using conditional knockout mice, we found that myeloid Hdac3 deficiency promotes collagen deposition in atherosclerotic lesions and thus induces a stable plaque phenotype. Also, macrophages presented a switch to anti‐inflammatory wound healing characteristics and showed improved lipid handling. The pro‐fibrotic phenotype was directly linked to epigenetic regulation of the Tgfb1 locus upon Hdac3 deletion, driving smooth muscle cells to increased collagen production. Moreover, in humans, HDAC3 was the sole Hdac upregulated in ruptured atherosclerotic lesions, Hdac3 associated with inflammatory macrophages, and HDAC3 expression inversely correlated with pro‐fibrotic TGFB1 expression. Collectively, we show that targeting the macrophage epigenome can improve atherosclerosis outcome and we identify Hdac3 as a potential novel therapeutic target in cardiovascular disease.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.15252/emmm.201404170

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 4 references

Cited by

See all 179

Metadata

Authors
Hoeksema, M. A., Gijbels, M. J., Van den Bossche, J., van der Velden, S., Sijm, A., Neele, A. E., Seijkens, T., Stöger, J. L., Meiler, S., Boshuizen, M. C., Dallinga‐Thie, G. M., Levels, J. H., Boon, L., Mullican, S. E., Spann, N. J., Cleutjens, J. P., Glass, C. K., Lazar, M. A., de Vries, C. J., Biessen, E. A., Daemen, M. J., Lutgens, E., & de Winther, M. P.
Venue
EMBO Molecular Medicine
Published
2014-07-09
Volume
6
Issue
9
Pages
1124-1132
ISSN
  • 1757-4676 (ISSN-L)
  • 1757-4684
OpenAlex
W2115806337
Cited by
179
References
4
FWCI
5.58
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Targeting macrophage Histone deacetylase 3 stabilizes atherosclerotic lesions. https://app.cochat.ai/papers/10.15252/emmm.201404170
The paper
Hoeksema, M. A., Gijbels, M. J., Van den Bossche, J., van der Velden, S., Sijm, A., Neele, A. E., Seijkens, T., Stöger, J. L., Meiler, S., Boshuizen, M. C., Dallinga‐Thie, G. M., Levels, J. H., Boon, L., Mullican, S. E., Spann, N. J., Cleutjens, J. P., Glass, C. K., Lazar, M. A., de Vries, C. J., . . . de Winther, M. P. (2014). Targeting macrophage Histone deacetylase 3 stabilizes atherosclerotic lesions. EMBO Molecular Medicine. https://doi.org/10.15252/emmm.201404170

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.